a leader in the field of digital therapeutics
Voluntis creates digital therapeutics that empower cancer patients and people with chronic conditions to self-manage their treatment every day, thus improving real-world outcomes. Voluntis’ solutions, combining mobile and web apps, use clinical algorithms to deliver personalized recommendations to patients and their care teams. Leveraging its Theraxium technology platform, Voluntis has designed and operates multiple digital therapeutics, especially in oncology and diabetes. The company is headquartered in Paris, France and Cambridge, MA, USA.
Why we invested in Voluntis
We believe that all oncology drugs will have a digital companion in the future. This is for a few reasons: Cancer treatments often cause side effects that need to be managed and monitored carefully. Patients need to be empowered to manage their treatment on a daily basis, receiving personalised support and guidance – which will have a big effect on the patients quality of life. Improved treatment adherence will also lead to improved outcomes. And for pharma companies, showing outcomes in real world will become a condition for reimbursement – it’s just a question of when. Voluntis positioning at the forefront of the rapidly growing digital therapeutics sector is perfectly aligned with Debiopharm’s priority areas of interest.
Discover how we can help you bring your ambition to life
November 23, 2020
Debiopharm invests in DTx leader Voluntis